RNF144A exerts tumor suppressor function in breast cancer through targeting YY1 for proteasomal degradation to downregulate GMFG expression

Yin-Ling Zhang1,2 · Jin-Ling Cao1 · Ye Zhang1 · Li Liao1,2 · Ling Deng1,2 · Shao-Ying Yang1,2 · Shu-Yuan Hu1,2 · Yan Ning3 · Fang-Lin Zhang1,2 · Da-Qiang Li1,2,4,5,6

Received: 15 November 2021 / Accepted: 13 December 2021 / Published online: 1 February 2022 © The Author(s) 2022

Abstract
Ring finger protein 144A (RNF144A), a poorly characterized member of the RING-in-between-RING family of E3 ubiquitin ligases, is an emerging tumor suppressor, but its underlying mechanism remains largely elusive. To address this issue, we used Affymetrix GeneChip Human Transcriptome Array 2.0 to profile gene expression in MDA-MB-231 cells stably expressing empty vector pCDH and Flag-RNF144A, and found that 128 genes were differentially expressed between pCDH-and RNF144A-expressing cells with fold change over 1.5. We further demonstrated that RNF144A negatively regulated the protein and mRNA levels of glial maturation factor γ (GMFG). Mechanistical investigations revealed that transcription factor YY1 transcriptionally activated GMFG expression, and RNF144A interacted with YY1 and promoted its ubiquitination-dependent degradation, thus blocking YY1-induced GMFG expression. Functional rescue assays showed that ectopic expression of RNF144A suppressed the proliferative, migratory, and invasive potential of breast cancer cells, and the noted effects were partially restored by re-expression of GMFG in RNF144A-overexpressing breast cancer cells. Collectively, these findings reveal that RNF144A negatively regulates GMFG expression by targeting YY1 for proteasomal degradation, thus inhibiting the proliferation, migration, and invasion of breast cancer cells.

Keywords Breast cancer · RNF144A · Protein degradation · YY1 · GMFG

Abbreviations
GMFG Glia maturation factor gamma
RNF144A Ring finger protein 144A
YY1 Yin Yang 1

Introduction
Protein posttranslational modification plays an important role in regulating the stability and activity of key-signaling proteins [1]. In particular, the ubiquitin–proteasome pathway is critically involved in maintaining cellular homeostasis of cytosol and nuclear proteins of eukaryotic cells [2]. This process is catalyzed by a ubiquitin-activating enzyme
(E1), a ubiquitin-conjugating enzyme (E2), and various E3 ubiquitin ligases [3]. E3 ubiquitin ligases play a key role in determining substrate specificity and catalyzing the transfer of ubiquitin from E2 enzyme to its substrates [4]. The human genome encodes about 600 E3 ubiquitin ligases, which are divided into three main families based on their structure and catalytic mechanism, including RING (really interesting new gene), HECT (homologous to the E6AP carboxyl terminus), and RBR (RING-in-between-RING) [4, 5]. RBR-type E3 protein ligases are defined by the presence of a RING1 domain, followed by an ‘in-between RING’ (IBR) domain, and a RING2 domain [6, 7]. Unlike classic HECT- and RING-type E3 ligases, RBR-type E3 ligases use a RING/HECT hybrid-like mechanism to catalyze the transfer of ubiquitin to target proteins for proteosomal degradation [8–10].

Emerging evidence shows that RBR-type E3 ligases exert essential roles in neurodegenerative disease, infection, inflammation, and cancer [11]. Ring finger protein 144A (RNF144A) is a poorly characterized member of the RBR family of E3 ligases [6]. Limited information shows that RNF144A promotes apoptosis during DNA damage [12] and under oxidative stress [13]. Consistently, loss of RNF144A contributes to carcinogen-induced bladder tumorigenesis [14]. We recently demonstrated that RNF144A is epigenetically silencing in breast cancer cells by promoter hypermethylation [15], suppresses breast cancer progression through promoting the degradation of oncoprotein heat-shock protein family A member 2 (HSPA2) [16], and regulates the sensitivity of breast cancer cells to poly(ADP-ribose) polymerase (PARP) inhibitors through modulating the degradation PARP1 [17]. Together, these results indicate that RNF144A acts as an emerging tumor suppressor, but its underlying mechanisms still remain poorly understood.

Glia maturation factor-γ (GMFG) is a 16.8-kDa protein that was initially identified as a growth and differentiation factor acting on neurons as well as glia in the vertebrate brain [18]. Subsequent studies revealed that GMFG is preferentially expressed in proliferative, microvascular endothelial, and inflammatory cells [18, 19], and is an important regulator for angiogenic sprouting during angiogenesis in zebrafish [20]. In addition, GMFG regulates monocyte migration through modulation of β1-integrin [21], neutrophil chemotaxis by modulating actin cytoskeleton reorganization [22], and the migration and adherence of human T lymphocytes [22]. Bioinformatic analysis of GMFG in pan-cancers revealed that GMFG causes different survivals for different cancers through modulating tumor progression, immune response status, and tissue-specific tumor microenvironment [23]. High expression of GMFG is associated with colorectal cancer metastasis [24] and poor prognosis of patients with epithelial ovarian cancer [25], glioblastoma, lower grade glioma, lung squamous cell carcinoma, ocular melanomas, and prostate cancer [23]. Consequently, downregulation of GMFG suppresses colorectal cancer cell migration and invasion [24]. Despite these advances, the biological function and related regulatory mechanism of GMFG in breast cancer are unclear.

Transcription factor YY1 has been shown to regulate gene transcription by either binding to gene promoter or as a cofactor of a variety of transcription factors in multicellular organisms [26]. YY1 is overexpressed in variety types of human cancer including breast [27, 28], colon [29], lung [30], glioma [31], bladder [32], and prostate [33], and plays essential roles in cell proliferation, cell viability, epithelial-mesenchymal transition, metastasis and drug/immune resistance [34, 35]. In breast cancer, YY1 promotes the stemness [34], clonogenicity, migration, invasion, and tumor formation of breast cancer cells [28, 36–38]. In addition, YY1 contributes to endocrine resistance [39] and chemoresistance [34] of breast cancer cells. Emerging evidence shows that YY1 undergoes proteasome-dependent degradation in cancer and other cells [40–43]. However, the regulatory mechanisms for YY1 degradation and downstream target genes of YY1 in breast cancer cells are still largely unknown.

In this study, we found that YY1 transcriptionally activates GMFG expression, and RNF144A interacts with YY1 and promotes its degradation through the ubiquitin–proteasome pathway, thus blocking YY1-mediated induction of GMFG expression in breast cancer cells. Eventually, functional rescue assays demonstrated that the inhibitory effects of RNF144A on breast cancer cell proliferation, migration, and invasion was reversed by re-expression of GMFG in RNF144A-overexpressing cells. Together, these findings reveal a previously unrecognized role of the RNF144A-YY1-GMFG axis in breast cancer progression.

Materials and methods

Cell culture and reagents

Human breast cancer cell lines, MDA-MB-231, Hs578T, and MCF-7, and human embryonic kidney 293T (HEK293T) cell line were obtained from Cell Bank of Type Culture Collection of Chinese Academy of Sciences (Shanghai, China) and Shanghai Key Laboratory of Breast Cancer (Fudan University, Shanghai, China). All cell lines were authenticated by detection of mycoplasma, DNA-fingerprinting, cell viability, and endotoxin. Cells were cultured in high-glucose DMEM media (BasalMedia, #L110) supplemented with 10% fetal bovine serum (FBS; ExCell Biol, #FSP500) and 1% penicillin/streptomycin (BasalMedia, #S110B), and were maintained at 37 °C in a humidified incubator with 5% CO₂. MG-132 and cycloheximide (CHX) were obtained from Selleck (#S2619) and Cell Signaling Technology (#2112S),
respectively. Other regents and chemicals were purchased from Sigma-Aldrich unless otherwise noted.

**Cell viability, colony-formation, migration, and invasion assays**

Cell viability was determined using Cell Counting Kit-8 (CCK-8) kit (Yeasen, #40203ES92) according to the manufacturer’s instructions. In brief, cultured cells suspended in culture medium were seeded in 96-well plates (1000 cells/well) in triplicate. In the following few days, 10 μl CCK-8 solution and 90 μl culture medium solution were added to each well. The plate was incubated for 2.5 h before measuring the absorbance at 450 nm wavelength using a microplate reader (SPECTROstar Nano, BMG Labtech). For colony-formation assays, cells were seeded in 6-well plates (1000 cells/well) in triplicate and cultured for 2–3 weeks. Survival colonies were photographed and counted after staining with 1% crystal violet. Transwell migration and invasion assays were performed using noncoated polycarbonate transwell inserts with 8-mm pore (Corning Falcon, #353097) and Matrigel Invasion Chambers (Corning, #354480), respectively. In brief, 5 × 10⁴ cells in 200 μl of serum-free medium were seeded in the top chamber, and 800 μl of growth medium containing 10% FBS was added into the lower chambers as a chemoattractant. After 24 h of incubation, cells were fixed and stained with 1% crystal violet, and migrated and invaded cells were counted under a microscope.

**Plasmid transfection and lentiviral infection**

Flag-RNF144A, V5-ubiquitin, short hairpin RNA-targeting RNF144A (shRNF144A), and corresponding control constructs have been described previously [16]. To generate HA-YY1 and HA-GMFG constructs, YY1 and GMFG cDNAs were amplified by PCR and then subcloned into the lentiviral vector pLVX-IRES-Neo (Biofeng, #632181). The primers used for molecular cloning are provided in Supplementary Tables S1. DNA sequence was verified by DNA sequencing (HuaGene Biotech, Shanghai, China). Transient plasmid transfection was performed using Neofect DNA transfection reagent (TengyiBio, #TF20120) according to the manufacturer’s instructions. For generating stable cell lines expressing cDNAs or short hairpin RNA (shRNAs), HEK293T cells were transfected with each lentivirus expression vector and packaging plasmid mix using Neofect DNA transfection reagents. After 48 h of transfection, the supernatant containing viruses was collected, filtered, and used for infecting target cells in the presence of 8 mg/mL of polybrene (Sigma, #9268). Cells were cultured in the presence of 2 mg/mL of puromycin (Sangon Biotech, #A610593) or 5 mg/mL of G418 (Sangon Biotech, #A600958-0005) for 1 to 2 weeks.

**siRNA transfection**

Three independent small interfering RNAs targeting YY1 (siYY1 #1-3) and corresponding negative control siRNA (siNC) were purchased from GenePharma (Shanghai, China). The siRNA target sequences are listed in Supplementary Table S2. The siRNA duplexes were transfected into cells using Lipofectamine 2000 transfection reagents (Invitrogen, #2041726) following the manufacturer’s instructions. Knockdown efficiency was validated by immunoblotting after 48 h of transfection.

**Quantitative real-time PCR**

Total RNA was extracted from cultured cells using TRIzol reagent (Invitrogen, #15596018) according to the manufacturer’s protocol, and then converted to cDNA using PrimeScript RT Master Mix (Takara, #RR036A). Quantitative real-time PCR (qPCR) assays were performed using SYBR Premix Ex Taq (Takara, #RR420) on an Eppendorf Mastercycler ep realplex4 instrument (Eppendorf). The PCR reaction program was consisted of a denaturation procedure at 95 °C for 95 s, followed by 40 cycles of 95 °C for 15 s, 55 °C for 15 s, and 72 °C for 45 s, and a final incubation procedure at 72 °C for 10 min. Expression levels of target genes were normalized to that of GAPDH. The primer sequences are provided in Supplementary Table S3.

**Dual luciferase reporter assays**

The promoter sequence for 2000 bp upstream of transcription start site of GMFG was cloned into the pLG3-basic vector. Then, 1 μg pGL3-GMFG or control vector was transfected into cells using Neofect DNA transfection reagents. After 48 h of transfection, the activity of GMFG promoter was determined using the dual-luciferase reporter assay system (Promega, #E1910) according to the manufacturer’s protocol. All assays were repeated at least three times.

**Immunoblotting assays**

Cells were collected after being washed with phosphate-buffered saline (PBS) for 3 times and lysed in RIPA lysis buffer containing 150 mM NaCl, 10 mM Tris (pH 7.2), 0.1% SDS, 1.0% Triton X-100, 1% deoxycholate, and 5 mM EDTA. Protein concentrations were determined using BCA protein quantification kit (Yeasen, #20201ES90). Cellular lysates were mixed with 4 x SDS-PAGE protein loading buffer, boiled at 100 °C for 5 min, separated on SDS-PAGE gels, and then transferred onto PVDF membranes (Millipore,
The membranes were then blocked with 5% BSA for 2 h and then incubated with corresponding primary antibodies at 4 °C overnight, followed by incubation with secondary antibodies according to standard protocol. Rabbit polyclonal anti-RNF144A antibody was purchased from Lifespan (#LS-C162648). Rabbit polyclonal antibodies against GMFG (#13625-1-AP) and YY1 (#66281-1-lg) were obtained from Proteintech. Mouse monoclonal anti-Flag (#F1804-1MG) and anti-Vinculin (#V9131) were obtained from Sigma-Aldrich. Rabbit monoclonal anti-HA antibody was purchased from Cell Signaling Technology (#3724).

**In vivo ubiquitination and cycloheximide (CHX) assays**

In vivo ubiquitination and cycloheximide (CHX) assays have been described previously [16]. For examining ubiquitination levels of YY1, cells were transfected with expression plasmids encoding HA-YY1, V5-ubiquitin, and Flag-RNF144A alone or in combination. After 36 h of transfection, cells were treated with 10 µM MG-132 for the indicated times and then total cellular lysates were subjected to IP and immunoblotting analyses with the indicated antibodies as described previously in details [16]. For CHX chase assays, cells were treated with or without 100 µg/ml CHX for the indicated times and then subjected to immunoblotting with the indicated antibodies.

**Statistical analysis**

All data are presented as mean ± SD from at least three independent experiments. Student’s t test was used to assess the difference for two groups, and P ≤ 0.05 was considered statistically significant.

**Results**

**Identification of target genes of RNF144A**

To gain mechanistic insights into the biological functions of RNF144A in breast cancer progression, we established MDA-MB-231 cell lines stably expressing empty vector pCDH and Flag-RNF144A by lentiviral infection. The expression status of RNF144A in resultant cell lines was verified by immunoblotting assays (Fig. 1A). Gene expression profiling using Affymetrix GeneChip Human Transcriptome Array (HTA2.0) revealed that 128 genes were upregulated and 43 genes were downregulated in Flag-RNF144A expressing cells compared to pCDH expressing cells (Fig. 1B). Gene ontology (GO) analysis of the molecular functions of 128 differentially expressed genes between pCDH- and Flag-RNF144A expressing cells (Fig. 1D) revealed that 128 genes were differentially expressed genes between pCDH- and Flag-RNF144A expressing cells.
differentially expressed between RNF144A-overexpressing cells and control cells with a fold-change threshold of ≥ 1.5. Among them, 43 genes were upregulated, whereas 85 genes were downregulated, in RNF144A-overexpressing cells compared to control cells (Fig. 1B, C and Supplementary Table S4). Gene ontology (GO) analysis revealed that the top 5 molecular functions of 128 differentially expressed genes were involved in calcium ion binding, structural molecule activity, heparin binding, GTPase activator activity, and peptidase inhibitor activity (Fig. 1D). Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis showed that the top 5 enriched pathways of 128 differentially expressed genes were rheumatoid arthritis, cell adhesion molecules, viral myocarditis, phagosome, and tuberculosis (Fig. 1E).

RNF144A negatively regulates GMFG expression

According to the above analysis, 4 genes with definite functions in human cancer, including GMFG, integrin subunit α 1 (ITGA1), C–C motif chemokine ligand 2 (CCL2) and G Protein-coupled receptor 65 (GPR65) were selected for further validation by qPCR. Results showed that the mRNA levels of GMFG, CCL2, and GPR65 were decreased in MDA-MB-231 cells stably expressing Flag-RNF144A compared to cells expressing empty vector pCDH (Fig. 2A–C). In contrast, there were no significant difference in the mRNA levels of ITGA1 between pCDH- and Flag-RNF144A-expressing cells (Fig. 2C). In addition, the mRNA levels of GMFG and ITGA1 were increased, whereas the mRNA levels of CCL2 and GPR65 were decreased, in MDA-MB-231 cells stably expressing shRNF144A relative to cells expressing shNC.
Based on these results, we therefore subsequently focused on addressing the regulatory mechanism of GMFG by RNF144A. Immunoblotting analysis showed that ectopic expression of RNF144A in MDA-MB-231 cells downregulated (Fig. 2G), whereas knockdown of endogenous RNF144A in MDA-MB-231 cells upregulated (Fig. 2H), the protein levels of GMFG. Similar results were also obtained in RNF144A-overexpressing Hs578T cells (Fig. 2I, J) and RNF144A-depleted MCF-7 cells (Fig. 2K, L). These results suggest that RNF144A negatively regulates GMFG expression in breast cancer cells.

**RNF144A suppresses breast cancer cell proliferation, migration, and invasion through, at least in part, regulating GMFG expression**

To address whether RNF144A acts as a tumor suppressor in breast cancer through regulating GMFG expression, we re-expressed GMFG in MDA-MB-231 and Hs578T cells stably expressing RNF144A (Fig. 3A). CCK8 and colony formation assays revealed that ectopic expression of RNF144A in MDA-MB-231 and Hs578T cells suppressed breast cancer cell proliferation (Fig. 3B) and colony formation (Fig. 3C, D), but the noted effects were partially rescued following re-expression of GMFG in RNF144A overexpressing cells. In addition, transwell migration and invasion assays

---

**Fig. 3** RNF144A suppresses breast cancer cell proliferation, migration, and invasion partially through regulating GMFG expression. A Establishment of stable MDA-MB-231 and Hs578T cell lines expressing Flag-RNF144A alone or in combination with HA-GMFG by lentiviral infection. Expression levels of RNF144A and GMFG in the established cell lines were verified by immunoblot analysis with the indicated antibodies. B, C, and D MDA-MB-231 and Hs578T cell lines expressing Flag-RNF144A alone or in combination with HA-GMFG were subjected to CCK-8 (B) and colony-formation assays (C, D). The representative survival colonies and corresponding quantitative results are shown in C and D, respectively. E and F MDA-MB-231 and Hs578T cell lines expressing Flag-RNF144A alone or in combination with HA-GMFG were subjected transwell migration and invasion assays. The representative images of migrated and invaded cells and corresponding quantitative results are shown in E and F, respectively. **p < 0.01; ***p < 0.001
showed that suppression of migratory and invasive potential of MDA-MB-231 and Hs578T cells by ectopic expression of RNF144A was partially restored by re-expression of GMFG in cells stably expressing RNF144A (Fig. 3E, F). Collectively, these results suggest that RNF144A suppresses breast cancer cell proliferation, migration, and invasion through, at least in part, regulating GMFG expression.

Transcription factor YY1 positively regulates GMFG expression

As RNF144A is not a putative transcription factor, we next examined potential transcription factors that bind to the promoter of GMFG using UCSC Genome Browser (https://genome.ucsc.edu) [44] and JASPAR (http://jaspar.genereg.net/) [45] programs, and identified transcription factor YY1 could regulate GMFG expression. To verify this notion, we transfected Hs578T and MCF-7 cells with three independent siRNAs targeting YY1 (siYY1 #1-3). Immunoblotting and qPCR assays showed that knockdown of YY1 reduced the protein and mRNA levels of GMFG in both cell lines (Fig. 4A, B). Luciferase reporter assays demonstrated that YY1 enhanced the promoter activity of GMFG in a dose-dependent manner (Fig. 4C). Moreover, co-transfection of RNF144A attenuated YY1-induced increase in GMFG promoter activity (Fig. 4D). These results suggest that transcription factor YY1 positively regulates GMFG expression, and this process is blocked in the presence of RNF144A.

RNF144A negatively regulates the stability of YY1

To address the molecular mechanism by which RNF144A blocks YY1-induced GMFG expression, we next examined whether RNF144A affects the stability of YY1. As shown in Fig. 5A, ectopic expression of RNF144A in MDA-MB-231 and Hs578T cells resulted in a decrease in the protein levels of YY1 and GMFG. In contrast, knockdown of endogenous RNF144A in MCF-7 and MDA-MB-231 cells upregulated...
the protein levels of YY1 and GMFG (Fig. 5B). Moreover, ectopic expression of Flag-RNF144A in HEK293T cells led to a reduction in the protein levels of HA-YY1 in a dose-dependent manner (Fig. 5C). To verify whether YY1 can be degraded through ubiquitin–proteasome pathway in breast cancer cells, MDA-MB-231, Hs578T, and MCF-7 cells were treated with proteasome inhibitor MG-132 for the indicated times. Immunoblotting analysis showed that the protein levels of YY1 were increased after MG-132 treatment in a time-dependent manner (Fig. 5D). As a positive control, MG-132 treatment resulted in a significant increase in the protein levels of p21, a known substrate of the ubiquitin–proteasome system [46]. Moreover, RNF144A-mediated downregulation of YY1 in Hs578T and MDA-MB-231 cells was restored following MG-132 treatment (Fig. 5E). Knockdown of RNF144A in MDA-MB-231 and MCF-7 cells extended the half-life of YY1 protein (Fig. 5F, G). Collectively, these results suggest that RNF144A negatively regulates the stability of YY1.

**RNF144A interacts with YY1 and promotes its ubiquitination**

To address how RNF144A regulates the stability of YY1, we next examined whether RNF144A interacts with YY1.

---

**Fig. 5** RNF144A negatively affects the stability of YY1 protein. A MDA-MB-231 and Hs578T cells stably expressing pCDH and Flag-RNF144A were subjected to immunoblotting analysis with the indicated antibodies. B MCF-7 and MDA-MB-231 cells stably expressing shNC and shRNF144A were subjected to immunoblotting analysis with the indicated antibodies. C HEK293T cells were transfected with HA-YY1 alone or in combination with increasing doses of Flag-RNF144A. After 48 h of transfection, cells were collected for immunoblotting analysis with the indicated antibodies. D Hs578T, MDA-MB-231, and MCF-7 cells were treated with DMSO or 10 μM of MG-132 for the indicated times, and then subjected to immunoblotting analysis with the indicated antibodies. E MDA-MB-231 and Hs578T cells stably expressing pCDH and Flag-RNF144A were treated with DMSO or 10 μM of MG-132 for 6 h, and then subjected to immunoblotting analysis with the indicated antibodies. F and G MDA-MB-231 and MCF-7 cell lines stably expressing shNC and shRNF144A were treated with DMSO or 100 μg/ml of CHX for the indicated times, and then subjected to immunoblotting analysis with the indicated antibodies. The representative images of immunoblotting and corresponding quantitative results (YY1/Vinculin) are shown in F and G, respectively.
To this aim, HEK293T cells were transfected with Flag-RNF144A or HA-YY1, then subjected to immunoprecipitation assays with either an anti-Flag or anti-HA antibody. Immunoblotting analysis showed that Flag-RNF144A interacted with endogenous YY1 in HEK293T cells (Fig. 6A), while HA-YY1 was co-immunoprecipitated with endogenous RNF144A (Fig. 6B), indicating that RNF144A and YY1 can interact with each other in vivo. To examine whether RNF144A regulates YY1 ubiquitination levels, HEK293T cells were transfected with HA-YY1, V5-ubiquitin, Flag-RNF144A alone or in combination. As shown in Fig. 6C, D, ectopic expression of Flag-RNF144A led to an increase in the ubiquitination levels of HA-YY1. These results suggest that RNF144A promotes the proteasomal degradation of YY1 by enhancing its polyubiquitination (Fig. 6E).

Discussion

Our previous studies showed that RNF144A is epigenetically silenced in breast cancer cells by promoter hypermethylation [15] and its expression levels are associated with favorable prognosis of breast cancer patients [16]. In this study, we provide new mechanistic insights into tumor suppressor function of RNF144A in breast cancer cells.

First, RNF144A targets transcription factor YY1 for proteasomal degradation. Accumulating evidence shows that YY1 is overexpressed in multiple cancer types and that increased YY1 levels correlate with poor clinical outcomes [47–49]. In breast cancer, YY1 functions as an oncogene and negatively regulates p27 expression [28]. Previous studies have demonstrated that E3 ubiquitin ligase Smurf2 regulates proteasomal degradation of YY1 in multiple model systems [40–43]. In addition, E3 ubiquitin ligase TRIP12 interacts with and ubiquitinates YY1, leading to its degradation [50]. In contrast, ubiquitin specific protease 21 (USP21) stabilizes YY1 in non-small-cell lung cancer cells via mediating its deubiquitination [51]. E3 SUMO-protein ligase Pias4 stimulates the sumoylation of YY1 and stabilizes YY1 [52]. In this study, we demonstrated that E3-ubiquitin ligase RNF144A interacts with YY1 and promotes its proteasomal degradation through ubiquitination-dependent pathway (Figs. 5 and 6). As RNF144A is downregulated in breast cancer cell lines and tumor tissues [15, 16], which could be partially contribute to overexpression of YY1 in breast cancer cells [28].

Second, YY1 transcriptionally activates GMFG expression, and this process is blocked by RNF144A. Transcription factor YY1 can activate or inactivate gene expression depending on interacting partners, promoter context and
chrchromatin structure, and may be involved in the transcriptional control of about 10% of the total mammalian gene set [47, 53]. In our study, we found that knockdown of YY1 results in a decrease in the protein and mRNA levels of GMFG. Moreover, ectopic expression of YY1 enhances the promoter activity of GMFG in a dose-dependent manner, whereas RNF144A significantly suppresses YY1-induced increase in the promoter activity of GMFG gene (Fig. 4). Previous studies have shown that high GMFG expression correlates with poor prognosis and promotes cell migration and invasion in epithelial ovarian cancer [25]. In addition, expression of GMFG is associated with colorectal cancer metastasis and its downregulation suppresses colorectal cancer cell migration and invasion [24]. We further demonstrated that RNF144A suppresses breast cancer cell growth, migration, and invasion through, at least in part, negatively regulating GMFG expression (Fig. 3).

In conclusion, the findings presented in this study suggest that RNF144A exerts tumor suppressor functions in breast cancer cells through targeting transcription factor YY1 for proteasomal degradation, thus blocking YY1-mediated transcriptional activation of GMFG expression in breast cancer cells. These results expand our current understanding of the mechanistic roles of RNF144A in breast cancer progression and lay a foundation for further exploring its clinical application to impede cancer development and progression or sensitize cancer cells to anticancer drugs.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s12032-021-01631-6.

Acknowledgements We sincerely acknowledge members in the Li laboratory for their technical assistance and helpful advice.

Author contributions YLZ, JLC, YZ, LL, LD, SY, and SYH performed experiments and analyzed data. YN, FLZ, and DQL supervised the entire project and designed the experiments. YLZ and DQL wrote the paper with the input from all authors. All authors read and approved the final manuscript.

Funding The work in the Li laboratory is supported, in whole or in part, by the National Natural Science Foundation of China (81572584, 81772805, and 82173275) and the National Key R&D Program of China (2017YFC0908400 and 2018YFE0201600).

Data availability All data generated or analyzed during this study are included in this manuscript.

Declarations

Conflict of interest The authors declare that they have no competing interests.

Ethical approval Not applicable.

Consent for publication Not applicable.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Cho Y, Kang HG, Kim SJ, Lee S, Jee S, Ahn SG, et al. Post-translational modification of OCT4 in breast cancer tumorigenesis. Cell Death Differ. 2018;25(10):1781–95.
2. Bhattacharyya S, Yu H, Min C, Matouschek A. Regulated protein turnover: snapshots of the proteasome in action. Nat Rev Mol Cell Biol. 2014;15(2):122–33.
3. Ciechanover A. The unravelling of the ubiquitin system. Nat Rev Mol Cell Biol. 2015;16(5):322–4.
4. Uchida C, Kitagawa M. RING-, HECT-, and RBR-type E3 ubiquitin ligases: involvement in human cancer. Curr Cancer Drug Targets. 2016;16(2):157–74.
5. Zheng N, Shabek N. Ubiquitin ligases: structure, function, and regulation. Annu Rev Biochem. 2017;86:129–57.
6. Smit JJ, Sixma TK. RBR E3-ligases at work. EMBO Rep. 2014;15(2):142–54.
7. Cotton TR, Lechentenberg BC. Chain reactions: molecular mechanisms of RBR ubiquitin ligases. Biochem Soc Trans. 2020;48(4):1737–50.
8. Nalden H, Rittinger K. RBR ligase-mediated ubiquitin transfer: a tale with many twists and turns. Nat Struct Mol Biol. 2018;25(6):440–5.
9. Dove KK, Stiegitz B, Duncan ED, Rittinger K, Klevit RE. Molecular insights into RBR E3 ligase ubiquitin transfer mechanisms. EMBO Rep. 2016;17(8):1221–35.
10. Reiter KH, Klevit RE. Characterization of RING-between-RING E3 ubiquitin transfer mechanisms. Methods Mol Biol. 2018;1844:3–17.
11. Wang P, Dai X, Jiang W, Li Y, Wei W. RBR E3 ubiquitin ligases in tumorigenesis. Semin Cancer Biol. 2020;67(Pt 2):131–44.
12. Ho SR, Mahanic CS, Lee YJ, Lin WC. RNF144A, an E3 ubiquitin ligase for DNA-PKcs, promotes apoptosis during DNA damage. Proc Natl Acad Sci USA. 2014;111(26):E2646–55.
13. Han SH, Kim KT. RNF144A induces ERK-dependent cell death under oxidative stress via downregulation of vaccinia-related kinase 3. J Sci 2020;133(21).
14. Ho SR, Lee YC, Ittmann MM, Lin FT, Chan KS, Lin WC. RNF144A deficiency promotes PD-L1 protein stabilization and carcinogen-induced bladder tumorigenesis. Cancer Lett. 2021;520:344–60.
15. Zhang Y, Yang YL, Zhang FL, Liao XH, Shao ZM, Li DQ. Epigenetic silencing of RNF144A expression in breast cancer cells through promoter hypermethylation and MBD4. Cancer Med. 2018;7(4):1317–25.
16. Yang YL, Zhang Y, Li DD, Zhang FL, Liu HY, Liao XH, et al. RNF144A functions as a tumor suppressor in breast cancer through ubiquitin ligase activity-dependent regulation of stability and oncogenic functions of HSPA2. Cell Death Differ. 2020;27(3):1105–18.
17. Zhang Y, Liao XH, Xie HY, Shao ZM, Li DQ. RBR-type E3 ubiquitin ligase RNF144A targets PARP1 for ubiquitin-dependent degradation and regulates PARP inhibitor sensitivity in breast cancer cells. Oncotarget. 2017;8(55):94505–18.

18. Asai K. Review of the research of glia maturation factor and cloning of human and rat glia maturation factor-gamma (GMFG) cDNA. Jpn J Psychopharmacol. 2001;21(1):15–20.

19. Ikeda K, Kundi RK, Ikeda S, Kobara M, Matsubara H, Quertermous T. Glia maturation factor-gamma is preferentially expressed in microvascular endothelial and inflammatory cells and modulates actin cytoskeleton reorganization. Circ Res. 2006;99(4):424–33.

20. Zuo P, Fu Z, Tao T, Ye F, Chen L, Wang X, et al. The expression of glia maturation factors and the effect of glia maturation factor-gamma on angiogenic sprouting in zebrafish. Exp Cell Res. 2013;319(5):707–17.

21. Aerbajinai W, Liu L, Zhu J, Kumkhaek C, Chin K, Rodgers GP. Glia maturation factor-gamma regulates monocyte migration through modulation of beta1-Integrin. J Biol Chem. 2016;291(16):8549–64.

22. Aerbajinai W, Liu L, Chin K, Zhu J, Parent CA, Rodgers GP. Glia maturation factor-gamma mediates neutrophil chemotaxis. J Leukoc Biol. 2011;90(3):329–38.

23. Lan A, Ren C, Wang X, Tong G, Yang G. Bioinformatics and survival analysis of glia maturation factor-gamma in pan-cancers. BMC Cancer. 2022;21(1):423.

24. Wang H, Chen Z, Chang H, Mu X, Deng W, Yuan Z, et al. Expression of glia maturation factor gamma is associated with colorectal cancer metastasis and its downregulation suppresses colorectal cancer cell migration and invasion in vitro. Oncol Rep. 2017;37(2):929–36.

25. Zuo P, Ma Y, Huang Y, Ye F, Wang P, Wang X, et al. High GMFG expression correlates with poor prognosis and promotes cell migration and invasion in epithelial ovarian cancer. Gynecol Oncol. 2014;132(3):745–51.

26. Gordon S, Akopyan G, Garban H, Bonavida B. Transcription factor YY1: structure, function, and therapeutic implications in cancer biology. Oncogene. 2006;25(8):1125–42.

27. Thomassen M, Tan Q, Kruse TA. YY1 expression correlates with poor prognosis and promotes cell migration and invasion in epithelial ovarian cancer. Gynecol Oncol. 2014;132(3):745–51.

28. Lee CM, Barber GP, Casper J, Clawson H, Diekhans M, Gonzalez JN, et al. UCSC genome browser enters 20th year. Nucleic Acids Res. 2020;48(D1):D756–61.

29. Fornes O, Castro-Mondragon JA, Khan A, van der Lee R, Zhang X, Richmond PA, et al. JASPAR 2020: update of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 2020;48(D1):D87–92.

30. Bloom J, Amador V, Bartolini F, DeMartino G, Pagano M. Proteasome-mediated degradation of p21 via N-terminal ubiquitylation. Cell. 2003;115(1):71–82.

31. Khachigian LM. The Yin and Yang of YY1 in tumor growth and suppression. Int J Cancer. 2018;143(3):460–5.

32. Zhang Q, Stovall DB, Inoue K, Sui G. The oncogenic role of Yin Yang 1. Crit Rev Oncog. 2011;16(3–4):163–97.

33. Atchison M, Basu A, Zaprazna K, Papasani M, Gonzalez JN, et al. Mechanisms of transcriptional regulation by Yin Yang 1. Front Cell Dev Biol. 2020;8:592164.